Scholarlink

Purpose <p>To evaluate changes in amyloid burden on serial amyloid PET before and after donanemab treatment in a real-world clinical cohort.</p> Methods <p>This retrospective study included 20 consecutive patients who underwent serial amyloid PET before and after donanemab treatment. Quantitative analysis was performed using Centiloid values and tracer-specific standardized uptake value ratios (SUVr). Visual assessment was also performed to determine amyloid-positive or amyloid-negative status before and after treatment.</p> Results <p>Centiloid values significantly decreased from 52.3 ± 23.4 at baseline to − 5.6 ± 16.5 at follow-up, with a mean change of − 58.0 (<i>p</i> &lt; 0.001). All patients showed a reduction in Centiloid values. In the flutemetamol group (n = 12), pons-referenced SUVr significantly decreased, while in the florbetapir group (n = 8), cerebellar-referenced SUVr also showed significant reductions (both <i>p</i> &lt; 0.001). On visual assessment, 17 of 20 patients (85%) converted from amyloid-positive to amyloid-negative status after treatment.</p> Conclusion <p>Serial amyloid PET demonstrated a substantial reduction in amyloid burden following donanemab treatment in this real-world cohort. Quantitative amyloid PET, particularly using Centiloid scaling, may be a useful tool for monitoring treatment response in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Yoichi Otomi,
  • Takayoshi Shinya,
  • Hideki Otsuka,
  • Hiroto Kasai,
  • Tomoki Matsushita,
  • Yukiko Takaoka,
  • Yuka Hiroshima,
  • Tomoyasu Matsubara,
  • Koji Fujita,
  • Yukiko Tomioka,
  • Masahito Nakataki,
  • Shusuke Numata,
  • Yuishin Izumi,
  • Masafumi Harada

摘要

Purpose

To evaluate changes in amyloid burden on serial amyloid PET before and after donanemab treatment in a real-world clinical cohort.

Methods

This retrospective study included 20 consecutive patients who underwent serial amyloid PET before and after donanemab treatment. Quantitative analysis was performed using Centiloid values and tracer-specific standardized uptake value ratios (SUVr). Visual assessment was also performed to determine amyloid-positive or amyloid-negative status before and after treatment.

Results

Centiloid values significantly decreased from 52.3 ± 23.4 at baseline to − 5.6 ± 16.5 at follow-up, with a mean change of − 58.0 (p < 0.001). All patients showed a reduction in Centiloid values. In the flutemetamol group (n = 12), pons-referenced SUVr significantly decreased, while in the florbetapir group (n = 8), cerebellar-referenced SUVr also showed significant reductions (both p < 0.001). On visual assessment, 17 of 20 patients (85%) converted from amyloid-positive to amyloid-negative status after treatment.

Conclusion

Serial amyloid PET demonstrated a substantial reduction in amyloid burden following donanemab treatment in this real-world cohort. Quantitative amyloid PET, particularly using Centiloid scaling, may be a useful tool for monitoring treatment response in clinical practice.